✦ LIBER ✦

Mo-P5:352 Risk reduction and safety of fluvastatin in patients with the metabolic syndrome

✍ Scribed by Winkler, K.; Abletshauser, C.; Gimpelewicz, C.; Bortolini, M.; Isaacsohn, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Tolerability of Dalcetrapib i

✍ Anne Carol Goldberg; Anton F.H. Stalenhoef; Regina Duttlinger-Maddux; David Kall 📂 Article 📅 2009 🏛 Elsevier 🌐 English ⚖ 275 KB

Abstract: P391 EFFECTS OF COMBINATION TH

✍ Winkler, K; Schewe, T; Pütz, G; Ödünc, N; Siegel, E; Abletshauser, C; Hoffmann, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 78 KB

P.1.h.003 Prevalence of metabolic syndro

✍ A. Benabarre; M.P. García-Portilla; L. Livianos; F. Mesa 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 62 KB

Poster #99 CNR1 AND RISK OF THE METABOLI

✍ Weiping Yu; Marc De Hert; Tim Moons; Stephan J. Claes; Christoph U. Correli; Ruu 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 88 KB

1.P.190 Efficacy and safety of fluvastat

✍ E. Acartürk; E. Akoǧlu; G. Akgün; N. Çobanoǧlu; U. Görpe; S. Güneri; D. Güzelsoy 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 373 KB

P448 THE ROLE OF METABOLIC SYNDROME AND

✍ Procopet, B.; Farcau, O.; Crisan, D.; Stefanescu, H.; Balagel, M.; Feier, D.; Ra 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 86 KB